These sites bind to coreceptor CCR5 or CXCR4 on the membrane of the host cell (center panel), an event that initiates steps that culminate in the fusion of the HIV envelope with the host cell ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

HIV infects cells by attaching to a protein on their surface, called CCR5. Some people have a genetic mutation that changes the shape of this protein, meaning HIV can no longer attach to their ...

HIV-1 entry into cells is an attractive target for new antiviral agents. But will inhibitors aimed at the CCR5 co-receptor force HIV-1 to evolve more virulent forms? Other targets for entry ...

Entry inhibitors stop HIV from entering human cells. These include fusion inhibitors, CCR5 inhibitors and attachment inhibitors. In order to enter a host cell, HIV must bind to two separate receptors ...

Computational analysis of the variations in the HIV-1 genome sequence that correlate with preferential binding to the CCR5 (C-C-motif receptor 5) or CXCR4 (C-X-C motif receptor 4) coreceptors in ...

The CCR5Δ32 variant reduces the expression of CCR5 receptors on CD4 + T cells, which HIV commonly uses to enter cells. Individuals carrying this variant exhibited lower CCR5 expression and lower ...

people with HIV received stem cells from a person who had natural resistance to HIV infection due to the presence of the double CCR5-delta-32 mutation. People with this rare genetic mutation do not ...

Dr He used CRISPR or Cas9, which stands for CRISPR-associated protein 9, to target a gene called CCR5, which codes for a protein used by the human immunodeficiency virus-1 (HIV-1) to enter cells.

the first HIV fusion inhibitor. [1] Coreceptor CCR5 antagonists, which provide a novel mechanism of action, are a recent addition to the armamentarium of antiretroviral agents. Maraviroc ...